Every 10-Q that Niagen Bioscience, Inc (NAGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NAGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAGE filings page.
Niagen Bioscience, Inc. reported higher profitability for the three months ended March 31, 2026, driven by its core Niagen® businesses and a divestiture gain. Net sales rose to $31.5 million from $30.5 million, led by growth in Tru Niagen® consumer products and food-grade Niagen® ingredient sales.
Net income increased to $6.3 million from $5.1 million, helped by a $4.8 million gain on the sale of the analytical reference standards and services segment. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Gross margin remained stable at about 63% as stronger e‑commerce mix offset shifts in ingredient margins.
Operating cash flow swung to a $1.2 million use of cash, mainly due to higher receivables and inventory to support demand. The company ended the quarter with $66.5 million in cash and cash equivalents and repurchased about 490,000 shares for $2.4 million. Management expects existing cash and operating cash flows to cover obligations for at least the next twelve months.
Niagen Bioscience (NAGE) reported strong Q3 2025 results. Net sales were $33,986 thousand, up from $25,580 thousand a year ago. Operating income rose to $4,236 thousand and net income reached $4,578 thousand, or $0.05 diluted earnings per share. Cash and cash equivalents were $64,290 thousand as of September 30, 2025.
For the nine months, net sales were $95,584 thousand with net income of $13,250 thousand. Operating cash flow was $12,825 thousand, reflecting improved profitability and working capital. Segment mix in Q3 showed Consumer Products at $26,017 thousand and Ingredients at $7,197 thousand. As of November 3, 2025, there were 79,806,139 common shares issued and outstanding.
The company received $2,650,000 from the Elysium California settlement. In a separate Delaware matter, a final judgment awarded $9.2 million in fees and costs plus interest; the company has appealed and disclosed a reasonably possible loss of approximately $10.4 million. Trade receivables totaled $8,506 thousand, with 64.9% concentrated among three customers, and major-customer sales in the quarter included Life Extension at 11.9% and A.S. Watson Group at 10.8%.